Neurosteroids for postpartum depression
Zuranolone and brexanolone for postpartum depression.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 5, 4, 1, 4, 2.
New guidelines and consensus this year
- Zuranolone and Brexanolone for the Treatment of Postpartum DepressionObstet Gynecol2026 Jan 1
All papers from the last 12 months
56 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse MechanismsCNS Drugs2026 NovPMID 42645703Review
- Perceptions and Attitudes Regarding Postpartum Depression on Reddit: Inductive Content AnalysisOnline J Public Health Inform2026 Oct 13PMID 42868266
- Sex differences in responses to neurosteroid therapy after preterm birthFront Neuroendocrinol2026 Oct 10PMID 42858773Review
- Pediatric Extrapolation in Neuropsychiatric Drug Development: Leveraging Pharmacokinetic and Pharmacodynamic Strategies to Facilitate FDA ApprovalsClin Pharmacol Ther2026 OctPMID 42533553Review
- Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysisPsychiatry Res2026 OctPMID 42401022Systematic review
- Profiling zuranolone as a treatment option for postpartum depressionExpert Rev Neurother2026 Sep 16PMID 42750260Review
- Safety evaluation of zuranolone in the management of postpartum depression: A real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS)Australas Psychiatry2026 Sep 8PMID 42711976
- The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeuticsJ Neuroendocrinol2026 SepPMID 42687222Review
- Neuroendocrine and neuroinflammatory mechanisms in postpartum depression: From hormonal withdrawal to central immune dysregulation and emerging therapeutic targetsJ Psychiatr Res2026 SepPMID 42143824Review
- Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational UncertaintyCureus2026 AugPMID 42751664Review
More psychiatry trends
All specialties →Gut microbiome and mental health
Links between the gut microbiome and depression or anxiety.
Psilocybin therapy
Psilocybin-assisted therapy for depression and other conditions.
Brain stimulation for depression
Transcranial magnetic stimulation, including accelerated theta-burst protocols, for depression.
Key point: Connectivity- or frequency- and connectivity-individualized accelerated iTBS failed to yield significant antidepressant benefits over sham stimulation in treatment-resistant depression.
MDMA-assisted therapy
MDMA combined with psychotherapy, mainly studied in PTSD.
Ketamine and esketamine for depression
Ketamine and esketamine for treatment-resistant depression.
Muscarinic antipsychotics
Xanomeline-trospium and other muscarinic drugs for schizophrenia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
zuranolone[tiab] OR brexanolone[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.